pulmonary fibrosis

Bristol Myers Squibb, pulmonary fibrosis, idiopathic pulmonary fibrosis, BMS-986278, Phase 2 results

BMS scores another phase 2 win for its pulmonary fibrosis drug

Anika Sharma

Bristol Myers Squibb (BMS) is making significant strides in the field of pulmonary fibrosis treatment, particularly with its lysophosphatidic acid ...